

# CITATION REPORT

List of articles citing

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

DOI: 10.1016/j.clinthera.2006.10.007  
Clinical Therapeutics, 2006, 28, 1556-68.

**Source:** <https://exaly.com/paper-pdf/39858289/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
453	A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. <b>2007</b> , 23, 1493-507		51
452	Sitagliptin enhancing incretin action. <b>2007</b> , 7, 134-139		5
451	Summarising the use of thiazolidinediones with insulin. <b>2007</b> , 7, 75-80		
450	DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. <b>2007</b> , 2, 567-572		
449	Indikationsgebiete inkretinbasierter Therapien: Analyse von Studienpopulation, Studiendesign und Effektivität in Exenatide- und DPP-4-Inhibitor-Studien. <b>2007</b> , 2, 315-320		
448	Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. <i>Diabetes Care</i> , <b>2007</b> , 30, 1344-50	14.6	160
447	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <i>Endocrine Practice</i> , <b>2007</b> , 13 Suppl 1, 1-68	3.2	446
446	The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. <b>2007</b> , 28, 253-83		285
445	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 1979-87	14.6	422
444	Finding new treatments for diabetes--how many, how fast... how good?. <b>2007</b> , 356, 437-40		159
443	Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. <b>2007</b> , 298, 194-206		822
442	Exploring treatment strategies for type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 2737-45	14.6	17
441	Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes?. <b>2007</b> , 68, 599-602		2
440	Newly approved and promising antidiabetic agents. <b>2007</b> , 62, 293-310		19
439	A 74-year-old woman with diabetes. <b>2007</b> , 297, 196-204		12
438	Sitagliptin: a novel drug for the treatment of type 2 diabetes. <b>2007</b> , 15, 264-71		36
437	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. <b>2007</b> , 14, 98-107		56

436	Clinical management strategies for type 2 diabetes. <b>2007</b> , Suppl, 9-14		2
435	Incretin-based therapies: mimetics versus protease inhibitors. <b>2007</b> , 18, 240-5		41
434	Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 2614-34	3.5	67
433	DPP-4 inhibitors. <b>2007</b> , 21, 517-33		133
432	Gliptins: a new class of oral hypoglycaemic agent. <b>2007</b> , 100, 671-7		21
431	Sitagliptin: a guide to its use in type 2 diabetes mellitus. <b>2007</b> , 23, 5-8		
430	Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. <b>2007</b> , 23, 905-17		49
429	Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. <b>2007</b> , 23, 933-44		43
428	Chapter 7 Case History: JANUVIA(Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. <b>2007</b> , 42, 95-109		11
427	Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. <b>2007</b> , 16, 533-45		40
426	Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?. <b>2007</b> , 91, 1107-23, ix		7
425	Sitagliptin. <b>2007</b> , 67, 587-97		56
424	Oral antidiabetic agents in type 2 diabetes. <b>2007</b> , 23, 945-52		68
423	Biology of incretins: GLP-1 and GIP. <b>2007</b> , 132, 2131-57		2457
422	[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. <b>2007</b> , 148, 579-87		2
421	DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. <i>Review of Diabetic Studies</i> , <b>2007</b> , 4, 126-33	3.6	9
420	The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. <b>2007</b> , 13, S2-16; quiz S17		8
419	Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. <i>Endocrine Practice</i> , <b>2007</b> , 13, 260-8	3.2	57

418	The dipeptidyl-peptidase-4 (DPP-4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus. <b>2007</b> , 24, 474-482		6
417	Current awareness: Pharmacoepidemiology and drug safety. <b>2007</b> , 16, i-xii		
416	Sitagliptin. <b>2007</b> , 6, 109-10		52
415	Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. <b>2007</b> , 81, 636-49		35
414	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. <b>2007</b> , 81, 761-7		139
413	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2007</b> , 9, 194-205	6.7	535
412	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. <i>Diabetes, Obesity and Metabolism</i> , <b>2007</b> , 9, 733-45	6.7	437
411	Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. <b>2007</b> , 61, 29-37		27
410	Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. <b>2007</b> , 61, 3-11		13
409	Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. <b>2007</b> , 61, 19-28		28
408	Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. <b>2007</b> , 27, 1163-80		39
407	Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. <b>2007</b> , 8, 53-68		14
406	New therapies for diabetes. <b>2007</b> , 8, 58-63; discussion 64-5		6
405	Gliptins: DPP-4 inhibitors to treat type 2 diabetes. <b>2007</b> , 8, 6-12		3
404	[New concepts in the treatment of type 2 diabetes]. <b>2007</b> , 48, 698, 700-7		2
403	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. <b>2007</b> , 7, 340-7		36
402	Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. <b>2007</b> , 17, 569-76		10
401	Inkretinmimetika und Inkretinverstärker. <b>2007</b> , 3, 387-398		1

400	[New oral antidiabetic agents--clinical perspectives]. <b>2008</b> , 49, 495-501		4
399	DPP4 inhibitors: a new approach in diabetes treatment. <b>2008</b> , 25, 627-43		58
398	Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. <b>2008</b> , 8, 14		98
397	Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. <b>2008</b> , 10, 401-9		42
396	Management of type 2 diabetes: the GLP-1 pathway. <b>2008</b> , 9, 18-24		2
395	Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes. <b>2008</b> , 19, 26-29		
394	Impaired glucose tolerance and incretins in chronic liver disease. <b>2008</b> , 23, 166-7		1
393	Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 1212-20	6.7	65
392	Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 1221-38	6.7	65
391	Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 545-55	6.7	199
390	Glucagon-like peptide-1-based therapies: new developments and emerging data. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 22-35	6.7	9
389	Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. <b>2008</b> , 66, 36-42		41
388	Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulphonylureas and metformin. <b>2008</b> , 28, 506-21		10
387	Improving Insulin Sensitivity: A Review of New Therapies. <b>2008</b> , 9, S28-S38		
386	Tratamiento combinado de la diabetes mellitus tipo 2. <b>2008</b> , 15, 159-170		
385	Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. <b>2008</b> , 13, 593-607		71
384	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. <b>2008</b> , CD006739		128
383	Fibroblast activation protein and chronic liver disease. <b>2008</b> , 13, 3168-80		48

382	New drugs for type 2 diabetes mellitus: what is their place in therapy?. <b>2008</b> , 68, 2131-62	82
381	Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. <b>2008</b> , 26, 639-48	27
380	New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. <b>2008</b> , 25, 913-25	51
379	[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. <b>2008</b> , 29, 881-90	2
378	Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. <b>2008</b> , 79, 291-8	175
377	Incretin-based therapies in type 2 diabetes: a review of clinical results. <b>2008</b> , 82 Suppl 2, S102-7	21
376	Hipoglucemia en pacientes diabéticos tipo 2. <b>2008</b> , 10, 1204-1207	
375	Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. <b>2008</b> , 24, 489-96	130
374	Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. <b>2008</b> , 34 Suppl 2, S78-90	20
373	La sitagliptine, inhibiteur de la DPP-IV : un nouvel anti-diabétique oral. <b>2008</b> , 2, 160-165	
372	Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. <b>2008</b> , 9, 1705-20	17
371	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. <b>2008</b> , 117, 574-84	154
370	Sitagliptin: an oral agent for glucose control. <b>2008</b> , 3, 691-697	1
369	New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. <b>2008</b> , 9, 1495-507	4
368	The role of incretins in glucose homeostasis and diabetes treatment. <b>2008</b> , 60, 470-512	552
367	Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. <b>2008</b> , 24, 385-99	27
366	Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. <b>2008</b> , 31, 371-9	12
365	Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. <b>2008</b> , 65, 521-31	15

364	Incretin-based therapies in type 2 diabetes mellitus. <b>2008</b> , 93, 3703-16	159
363	The entero-insular axis: implications for human metabolism. <b>2008</b> , 46, 43-56	31
362	Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. <b>2008</b> , 51, 141-7	105
361	Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. <b>2008</b> , 29, 367-79	80
360	Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. <b>2008</b> , 10, 247-56	39
359	Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies. <b>2008</b> , 34, 183-200	2
358	Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. <b>2008</b> , 61, 401-9	45
357	Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. <b>2008</b> , 24, 2189-202	10
356	Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use. <b>2008</b> , 26, 53-57	30
355	More choices than ever before: emerging therapies for type 2 diabetes. <b>2008</b> , 34, 518-34	27
354	Recent advances in the management of type 2 diabetes mellitus: a review. <b>2008</b> , 84, 524-31	45
353	Approaches to treatment of type 2 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 1697-703	14.6 9
352	Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. <b>2008</b> , 17, 845-53	39
351	Inkretinbasierte Antidiabetika im Vergleich: GLP-1-Mimetika und DPP-IV-Inhibitoren. <b>2008</b> , 3, 234-240	
350	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. <b>2008</b> , 24, 3009-22	9
349	Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. <b>2008</b> , 24, 401-17	12
348	Glucagon like peptides-1 modulators as newer target for diabetes. <b>2008</b> , 9, 911-20	2
347	Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. <b>2008</b> , 4, 101-9	40

346	Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes. <b>2008</b> , 2, 162-171		1
345	Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. <b>2008</b> , 15, 484-91		13
344	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. <b>2008</b> , 11, 491-9		76
343	New combination treatments in the management of diabetes: focus on sitagliptin-metformin. <b>2008</b> , 4, 743-51		33
342	Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. <b>2008</b> , 4, 1221-7		25
341	Hypoglycemia associated with off-label sitagliptin use. <b>2008</b> , 1, 3-5		
340	Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. <b>2008</b> , 4, 753-68		108
339	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. <b>2008</b> , 4, 383-94		55
338	The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. <b>2008</b> , 14, S2-14; quiz 15-6		7
337	Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. <b>2008</b> , 13, 3648-60		60
336	Managed care perspective on three new agents for type 2 diabetes. <b>2008</b> , 14, 363-80		29
335	Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. <b>2008</b> , 52, 1039-49		10
334	Management of diabetes mellitus on Yom Kippur and other Jewish fast days. <i>Endocrine Practice</i> , <b>2008</b> , 14, 305-11	3.2	9
333	Efficacy and safety of incretin based therapies: clinical trial data. <b>2009</b> , 49 Suppl 1, S30-40		54
332	Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. <b>2009</b> , 1, 1103-1119		1
331	Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. <b>2009</b> , 5, 683-98		9
330	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 23-30	3-4	1
329	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 127-134	3-4	3



328	Incretin-based therapy of type 2 diabetes mellitus. <b>2009</b> , 10, 46-55	37
327	Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. <b>2009</b> , 15, 696-700	5
326	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <b>2009</b> , 76 Suppl 5, S28-38	48
325	Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. <b>2009</b> , 54, 516-23	148
324	Treating type 2 diabetes: incretin mimetics and enhancers. <b>2009</b> , 3, 387-95	5
323	Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. <b>2009</b> , 3, 68-82	16
322	New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. <b>2009</b> , 35, 731-4, 738-40, 742-4 passim	7
321	Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. <b>2009</b> , 121, 40-5	30
320	Treatment Considerations for Diabetes: A Pharmacist's Guide to Improving Care in the Elderly. <b>2009</b> , 22, 575-587	1
319	DPP-4 inhibitors in clinical practice. <b>2009</b> , 121, 70-100	27
318	Impact of sitagliptin on markers of beta-cell function: a meta-analysis. <b>2009</b> , 337, 321-8	35
317	Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. <b>2009</b> , 117, 522-57	74
316	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. <b>2009</b> , 37, 7-21	2
315	Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. <b>2009</b> , 4, 32-64	44
314	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. <b>2009</b> , 121, 94-107	68
313	Novel Approaches to the Treatment of Type 2 Diabetes. <b>2009</b> , 22, 320-332	3
312	Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. <b>2009</b> , 94, 4810-9	187
311	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. <b>2009</b> , 124, 113-38	143

310	The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. <b>2009</b> , 602, 448-54	29
309	Recent and emerging anti-diabetes targets. <b>2009</b> , 29, 125-95	70
308	Update in new medications for primary care. <b>2009</b> , 24, 111-7	1
307	DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. <b>2009</b> , 26, 272-80	6
306	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. <b>2009</b> , 26, 488-99	59
305	Sample size determination for constrained longitudinal data analysis. <b>2009</b> , 28, 679-99	21
304	Treatment options for type 2 diabetes:introducing the incretin-based therapies. <b>2009</b> , 26, 179-183ii	2
303	The role of incretin-based therapies in the management of type 2 diabetes. <b>2009</b> , 26, 186-188i	0
302	Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. <b>2010</b> , 40, 50-61	69
301	New treatments in type 2 diabetes: a focus on the incretin-based therapies. <b>2009</b> , 70, 343-53	36
300	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <b>2009</b> , 8, 369-85	323
299	New developments in incretin-based therapies: the current state of the field. <b>2009</b> , 21 Suppl 1, 631-41	2
298	The metabolic syndrome and schizophrenia. <b>2009</b> , 119, 4-14	193
297	Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 1009-16	6.7 19
296	Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. <b>2009</b> , 157, 415-26	38
295	Exenatide once weekly for the treatment of type 2 diabetes. <b>2009</b> , 18, 359-67	35
294	Targeting the incretin system in type 2 diabetes mellitus. <b>2009</b> , 76, 244-56	3
293	Incretin-based therapies for type 2 diabetes mellitus. <b>2009</b> , 5, 262-9	510

292	Incretin therapies: effects beyond glycemic control. <b>2009</b> , 20 Suppl 2, S319-28		16
291	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 20 Suppl 2, S309-18		20
290	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 122, S11-24		41
289	Incretin therapies: effects beyond glycemic control. <b>2009</b> , 122, S25-36		27
288	Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. <b>2009</b> , 25, 569-83		111
287	DPP-4 inhibitors. <b>2009</b> , 4, 15-31		6
286	Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. <b>2009</b> , 23, 487-98		82
285	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. <b>2009</b> , 25, 2361-71		113
284	Insulin Resistance. <b>2009</b> ,		
283	Diabetes medications and body weight. <b>2009</b> , 8, 573-84		93
282	Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. <i>Endocrine Practice</i> , <b>2009</b> , 15, 750-62	3.2	4
281	Pharmacotherapy of hyperglycemia. <b>2009</b> , 10, 2415-32		11
280	Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. <b>2009</b> , 18, 1405-11		19
279	Managing diabetes in hemodialysis patients: observations and recommendations. <b>2009</b> , 76, 649-55		49
278	Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes. <b>2009</b> , 23, 228-235		9
277	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. <b>2009</b> , 18, 1495-503		62
276	Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes. <b>2009</b> , 1, CMT.S2313		1
275	Insulin, other hypoglycemic drugs, and glucagon. <b>2009</b> , 689-702		0

274	Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. <b>2009</b> , 5, 92-101		9
273	Incretin-Based Therapies in Patients with Type 2 Diabetes. <b>2010</b> , 5, 75-85		
272	Preservation of beta-cell function in type 2 diabetes. <i>Endocrine Practice</i> , <b>2010</b> , 16, 1038-55	3.2	17
271	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 31-41	3.4	31
270	Managing type 2 diabetes in the primary care setting: beyond glucocentricity. <b>2010</b> , 340, 133-43		4
269	Incretin therapy for type 2 diabetes mellitus. <b>2010</b> , 27, 881-94		1
268	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 887-95	12.7	93
267	Glycaemic control in type 2 diabetes: targets and new therapies. <b>2010</b> , 125, 328-61		130
266	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. <b>2010</b> , 30, 463-84		103
265	Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. <b>2010</b> , 30, 609-24		43
264	[Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP-4 inhibitors. Contributions with respect to other families of oral antidiabetic agents]. <b>2010</b> , 42 Suppl 1, 33-40		1
263	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. <b>2010</b> , 10, 7		207
262	Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. <b>2010</b> , 64, 791-801		23
261	Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. <b>2010</b> , 64, 1601-8		15
260	Emerging treatment options for type 2 diabetes. <b>2010</b> , 70, 631-44		42
259	Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 1-11	6.7	36
258	Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 167-77	6.7	262
257	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 929-40	6.7	20

256	Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. <b>2010</b> , 2, 7-19	12
255	Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. <b>2010</b> , 6, 17-26	1
254	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. <b>2010</b> , 6, 541-8	80
253	Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. <b>2010</b> , 34, 331-7	7
252	Current developments in the treatment of diabetes: the incretin therapies. <b>2010</b> , 10, 21-30	1
251	Hypoglycaemia in patients with type 2 diabetes: minimising the risk. <b>2010</b> , 10, 35-41	3
250	A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. <b>2010</b> , 86, 44-57	96
249	Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. <b>2010</b> , 14, 1-248	99
248	Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. <b>2010</b> , 122, 71-80	39
247	Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus. <b>2010</b> , 10, 274-283	12
246	Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. <b>2010</b> , 26, 1333-42	23
245	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. <b>2010</b> , 122, 52-60	16
244	Sitagliptin-induced hemolysis. <b>2010</b> , 42, 320-1	8
243	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. <b>2010</b> , 102, 511-23	5
242	Behandlung des Typ-2-Diabetes mit Sitagliptin [Eine nichtinterventionelle Studie. <b>2010</b> , 5, 242-250	
241	Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. <b>2010</b> , 122, 172-83	7
240	Incretin-based therapy in chronic kidney disease. <b>2010</b> , 17, 439-49	5
239	Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. <b>2010</b> , 85, S38-49	14

238	Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. <b>2010</b> , 85, S27-37	39
237	Dipeptidyl Peptidase 4 Inhibitors. <b>2010</b> , 39-76	1
236	Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. <b>2010</b> , 70, 489-512	75
235	Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. <b>2010</b> , 49, 573-88	119
234	Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. <b>2010</b> , 70, 1945-61	51
233	Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. <b>2010</b> , 19, 1017-25	9
232	Incretin-based therapies: review of current clinical trial data. <b>2010</b> , 123, S28-37	88
231	Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. <b>2010</b> , 123, S38-48	87
230	Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. <b>2010</b> , 8, 405-18	66
229	Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. <b>2010</b> , 30, 855-66	14
228	[Management of type 2 diabetes: from guidelines to clinical practice]. <b>2010</b> , 135 Suppl 2, 9-14	0
227	[Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors]. <b>2010</b> , 135 Suppl 2, 33-9	2
226	Incretin-based therapy and type 2 diabetes. <b>2010</b> , 84, 389-413	18
225	Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. <b>2011</b> , 34, 69-77	18
224	Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. <b>2011</b> , 35, 518-27	3
223	DPP-4 inhibitors and angioedema: a cause for concern?. <b>2011</b> , 106, 436-8	13
222	DPP IV inhibitors: successes, failures and future prospects. <b>2011</b> , 5, 105-12	21
221	Type 2 Diabetes in Adults. <b>2011</b> , 77-137	3

220	Incretin-based therapies and their future in Type 2 diabetes mellitus. <b>2011</b> , 8, 143-152		1
219	Sitagliptin: a review. <b>2011</b> , 12, 1613-22		30
218	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. <b>2011</b> , 71, 1441-67		166
217	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. <b>2011</b> ,		6
216	Pharmacological management of type 2 diabetes mellitus: an update. <b>2011</b> , 7, 392-405		54
215	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. <b>2011</b> , 124, S3-18		220
214	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. <b>2011</b> , 124, S19-34		54
213	Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. <b>2011</b> , 37, 477-88		38
212	Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. <b>2011</b> , 2, 377-80		13
211	Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. <b>2011</b> , 2, 381-90		20
210	Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. <b>2011</b> , 3, CMT.S6227		1
209	Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. <b>2011</b> , 35, 117-8		
208	Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus. <b>2011</b> ,		
207	Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. <b>2011</b> , 35, 159-65		42
206	Response: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65). <b>2011</b> , 35, 300-1		1
205	Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. <b>2011</b> , 6, 543-556		
204	Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 7-18	6.7	367
203	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 99-117	6.7	30

202	Dipeptidyl peptidase-4 inhibitors and HbA1c target of . <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 594-603	6.7	82
201	Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 604-14	6.7	17
200	The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 644-52	6.7	68
199	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of $\beta$ cell function in patients with type 2 diabetes. <b>2011</b> , 65, 154-64		46
198	Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. <b>2011</b> , 65, 930-8		32
197	Update on incretin hormones. <b>2011</b> , 1243, E55-74		88
196	Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. <b>2011</b> , 43, 2113-5		8
195	Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 511-27	3.5	70
194	Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 528-76	3.5	39
193	Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 1005-22	3.5	35
192	Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. <i>Diabetology International</i> , <b>2011</b> , 2, 32-44	2.3	34
191	Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. <i>Diabetology International</i> , <b>2011</b> , 2, 94-105	2.3	9
190	Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2011</b> , 27, 362-72	7.5	57
189	A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*. <b>2011</b> , 119, 401-7		6
188	Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. <b>2011</b> , 123, 63-70		13
187	Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. <b>2011</b> , 13, 27-32		14
186	Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes. <b>2011</b> , 5, 1529-48		76
185	Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. <b>2011</b> , 8, 125-35		55



184	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. <b>2011</b> , 24, 26-35	5
183	Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. <b>2011</b> , 12, 2055-67	1
182	Review of approved pioglitazone combinations for type 2 diabetes. <b>2011</b> , 12, 1571-84	9
181	Choosing a gliptin. <b>2011</b> , 15, 298-308	51
180	Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. <b>2011</b> , 123, 53-65	14
179	The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. <b>2012</b> , 4, 227-37	51
178	Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. <b>2012</b> , 3, 498-502	18
177	The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation. <b>2012</b> , 6, 665-73	11
176	Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. <b>2012</b> , 69, 1044-8	4
175	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. <b>2012</b> , 7, 205-217	4
174	Recent advances in incretin-based therapies. <b>2012</b> , 77, 489-99	54
173	Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. <b>2012</b> , 46, 1453-69	76
172	DPP-4 inhibition and islet function. <b>2012</b> , 3, 3-10	15
171	Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. <b>2012</b> , 2, 1	2
170	Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. <b>2012</b> , 5, 154-65	11
169	Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. <b>2012</b> , 97, 1615-22	78
168	DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. <b>2012</b> , 38, 89-101	133
167	Newer Diabetes Medications. <b>2012</b> , 375-417	

166	Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. <b>2012</b> , 29, 736-46		61
165	Incretin-based therapies. <b>2012</b> , 4, 55-67		29
164	Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 101-11	6.7	50
163	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1247-1258.e22	3.5	200
162	DPP-4 inhibitors in the treatment of type 2 diabetes. <b>2012</b> , 83, 823-32		66
161	Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. <b>2012</b> , 14, 435-46		26
160	Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. <b>2012</b> , 77, 215-23		32
159	Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 481-92	6.7	18
158	The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14 Suppl 2, 4-12	6.7	8
157	Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 745-52	6.7	30
156	Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 795-802	6.7	66
155	Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 1061-72	6.7	108
154	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. <b>2012</b> , 4, 8		13
153	DPP-4 inhibitors and lipids: systematic review and meta-analysis. <b>2012</b> , 29, 14-25		155
152	Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. <i>Diabetes Therapy</i> , <b>2013</b> , 4, 119-45	3.6	98
151	Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. <i>Diabetology International</i> , <b>2013</b> , 4, 160-172	2.3	22
150	Diabetes. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> ,	3.6	7
149	Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. <b>2013</b> , 12, 3		72

148	Dipeptidyl Peptidase-4 Inhibitors. <b>2013</b> , 33-45		
147	Complementing insulin therapy to achieve glycemic control. <b>2013</b> , 30, 557-76		28
146	Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. <b>2013</b> , 50, 827-35		14
145	The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. <i>Endocrine Practice</i> , <b>2013</b> , 19, 1050-61	3.2	23
144	Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 1101-10	6.7	20
143	Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. <b>2013</b> , 18, 708-15		24
142	The cardiovascular safety of incretin-based therapies: a review of the evidence. <b>2013</b> , 12, 130		33
141	Oligomers-model building in protonation equilibria of sitagliptin. <b>2013</b> , 11, 1799-1807		1
140	A review of the efficacy and safety of oral antidiabetic drugs. <b>2013</b> , 12, 153-75		205
139	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. <b>2013</b> , 5, 241-53		8
138	Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. <b>2013</b> , 56, 696-708		282
137	Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. <b>2013</b> , 47, 490-505		28
136	Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 593-606	6.7	38
135	Retinal and lens protective effect of sitagliptin in streptozotocin induced type-I diabetic wistar rats. <b>2013</b> , 3, 65-73		2
134	A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. <b>2013</b> , 3,		27
133	Non-insulin treatments for diabetes. <b>2013</b> , 20, 377-84		2
132	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. <b>2013</b> , 20, 638-53		8
131	Impact of three oral antidiabetic drugs on markers of $\beta$ cell function in patients with type 2 diabetes: a meta-analysis. <i>PLoS ONE</i> , <b>2013</b> , 8, e76713	3.7	10

130	Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. <b>2013</b> , 5, 68-79		35
129	Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. <b>2013</b> , 67, 759-67		13
128	Addition of sitagliptin to ongoing metformin monotherapy improves glyceic control in Japanese patients with type 2 diabetes over 52 weeks. <b>2013</b> , 4, 174-81		20
127	Sitagliptin added to voglibose monotherapy improves glyceic control in patients with type 2 diabetes. <b>2013</b> , 4, 595-604		20
126	Efficacy and safety of sitagliptin as add-on therapy on glyceic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. <b>2013</b> , 60, 1207-14		24
125	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <b>2013</b> , 9, 273-82		5
124	The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity. <i>PLoS ONE</i> , <b>2013</b> , 8, e63626	3-7	42
123	Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. <b>2013</b> , 28, 881-7		9
122	A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. <b>2013</b> , 7, 893-903		12
121	Glyceic Control in Diabetic Patients on Long-Term Maintenance Dialysis. <b>2013</b> ,		2
120	Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. <b>2014</b> , 8, 2283-94		4
119	Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. <b>2014</b> , 20, 120-9		8
118	GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. <b>2014</b> , 8, 677-88		2
117	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. <b>2014</b> , 05,		1
116	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. <b>2014</b> , 10, 787-812		42
115	The effect of alogliptin and pioglitazone combination therapy on various aspects of $\beta$ cell function in patients with recent-onset type 2 diabetes. <b>2014</b> , 170, 565-74		29
114	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. <b>2014</b> , 70, 1277-89		5
113	Diabetes mellitus: An overview. <b>2014</b> , 1-57		3

112	Determinants of pharmaceutical sales representative access limits to physicians. <b>2014</b> , 14, 220-243		9
111	Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. <b>2014</b> , 32, 170-7		5
110	Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. <b>2014</b> , 31, 203-14		29
109	Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. <b>2014</b> , 70, 907-22		12
108	Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. <b>2014</b> , 24, 689-97		148
107	Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. <b>2014</b> , 74, 223-42		65
106	Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 223-30	6.7	31
105	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , <b>2014</b> , 37, 2647-59	14.6	48
104	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 48-56	6.7	73
103	A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. <b>2014</b> , 22, 403-10		16
102	Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate. <b>2014</b> , 14, 191-207		12
101	Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. <b>2014</b> , 61, 447-56		6
100	Implications of incretin-based therapies on cardiovascular disease. <b>2015</b> , 69, 531-49		10
99	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open label, non-inferiority trial. <b>2015</b> , 6, 182-91		15
98	Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. <b>2015</b> , 7, 313-23		2
97	Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes. <i>Journal of Clinical Medicine Research</i> , <b>2015</b> , 7, 211-9	2.9	14
96	Sitagliptin: Is It Effective in Routine Clinical Practice?. <b>2015</b> , 2015, 950571		3
95	A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. <b>2015</b> , 69, 626-31		21

94	Pharmacologic treatment of type 2 diabetes: oral medications. <b>2015</b> , 49, 540-56		54
93	Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on $\beta$ cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. <b>2015</b> , 7, 347-59		32
92	Sitagliptin for Type 2 diabetes: a 2015 update. <b>2015</b> , 13, 597-610		15
91	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. <i>Diabetes Therapy</i> , <b>2015</b> , 6, 127-42	3.6	32
90	Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. <b>2015</b> , 31, 1071-7		2
89	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <b>2015</b> , 127, 463-79		10
88	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. <b>2015</b> , 41, 19S-31S		5
87	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. <i>Diabetes Therapy</i> , <b>2015</b> , 6, 239-56	3.6	64
86	Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. <b>2015</b> , 23, 132-40		28
85	Incretin-based therapies. <b>2015</b> , 99, 107-29		22
84	The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. <b>2016</b> , 82, 301-14		19
83	DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. <b>2016</b> , 116, 288-98		46
82	Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. <b>2016</b> , 95, e2386		18
81	Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats. <b>2016</b> , 241, 1577-87		42
80	New fixed dose chemical combinations: the way forward for better diabetes type II management?. <b>2016</b> , 17, 2207-2214		6
79	DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2016</b> , 32, 391-404	7.5	47
78	Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. <b>2016</b> , 30, 1282-6		1
77	NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. <b>2016</b> , 8, 334ra51		135

76	Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2016</b> , 17, 40	2.6	4
75	Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. <b>2016</b> , 16, 70		11
74	A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. <b>2016</b> , 8, 701-11		14
73	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. <b>2016</b> , 17, 1591-8		2
72	A systematic review of the safety of incretin-based therapies in type 2 diabetes. <b>2016</b> , 11, 217-232		4
71	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. <i>BMJ, The</i> , <b>2016</b> , 352, i610	5.9	155
70	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. <b>2017</b> , 19, 25		1
69	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. <b>2017</b> , 5, E152-E177		47
68	Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. <b>2017</b> , 7, 44865		19
67	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1780-1789.e33	3.5	21
66	Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study. <i>Diabetology International</i> , <b>2018</b> , 9, 56-65	2.3	1
65	Synthesis of 4-(Trifluoromethyl)cyclopentenones and 2-(Trifluoromethyl)furans by Reductive Trifluoroacetylation of Ynones. <b>2017</b> , 19, 6602-6605		12
64	Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. <b>2017</b> , 8, 321-329		12
63	Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. <b>2017</b> , 37, 219-232		7
62	Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. <b>2017</b> , 8, 155-160		20
61	Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. <b>2017</b> , 17, 143-155		30
60	Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. <b>2018</b> , 74, 561-569		7
59	Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice. <b>2018</b> , 830, 95-104		3

58	Discovery and structure-activity relationships study of thieno[2,3-b]pyridine analogues as hepatic gluconeogenesis inhibitors. <b>2018</b> , 152, 307-317		20
57	Treatment with Oral Drugs. <b>2018</b> , 1-44		
56	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 78, 13-42	12.7	103
55	Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 786-799	6.7	13
54	Treatment with Oral Drugs. <b>2018</b> , 527-569		
53	Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1581-1589	3.6	3
52	Current Antidiabetic Drugs: Review of Their Efficacy and Safety. <b>2018</b> , 455-473		7
51	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 376	5.7	36
50	Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. <i>Bioscience Reports</i> , <b>2019</b> , 39,	4.1	1
49	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 408-411	6.7	2
48	Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost. <i>Diabetology International</i> , <b>2020</b> , 11, 49-56	2.3	
47	Quantum Chemical Calculation and DFT Study of Sitagliptin: Insight from Computational Evaluation and Docking Approach. <i>Journal of Nepal Physical Society</i> , <b>2020</b> , 6, 73-83	0	1
46	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , <b>2020</b> , 43, 1948-1957	14.6	21
45	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , <b>2020</b> , 18, 322	11.4	1
44	Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2020</b> , 21, 68	2.6	3
43	Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 2119-2127	3.4	1
42	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 178	5.7	43
41	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 107, 154242	12.7	8



40	Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2021</b> , 37, e3391	7.5	3
39	Dipeptidyl Peptidase 4 Inhibitors. 1-48		
38	The Role of Incretins in Insulin Secretion. <b>2010</b> , 57-74		1
37	Management and treatment of diabetes mellitus. <i>Advances in Experimental Medicine and Biology</i> , <b>2012</b> , 771, 356-80	3.6	16
36	Oral Agents for Type-2 Diabetes. <b>2011</b> , 93-122		1
35	Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis. <b>2009</b> , 41-75		1
34	Non-Insulin Agents for Diabetes. <b>2012</b> , 61-89		1
33	Glycemic Management. <i>Endocrine Practice</i> , <b>2007</b> , 13, 16-34	3.2	3
32	Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126177	3.7	14
31	Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139367	3.7	17
30	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153502	3.7	5
29	Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174295	3.7	65
28	Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. <i>Review of Diabetic Studies</i> , <b>2008</b> , 5, 73-94	3.6	82
27	The role of incretin therapy at different stages of diabetes. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 323-38	3.6	20
26	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 127-34	3.4	2
25	Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , <b>2019</b> , 57, 233-240	1.5	12
24	Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. <i>Journal of Clinical Medicine Research</i> , <b>2012</b> , 4, 251-8	2.9	16
23	Gliptins: a new class of oral antidiabetic agents. <i>Indian Journal of Pharmaceutical Sciences</i> , <b>2009</b> , 71, 608-14		13

22	MANAGEMENT OF DIABETES MELLITUS ON YOM KIPPUR AND OTHER JEWISH FAST DAYS. <i>Endocrine Practice</i> , <b>2008</b> , 14, 305-311	3.2	2
21	Quinazolin derivatives as emerging alpha-glucosidase inhibitors. <i>European Journal of Chemistry</i> , <b>2018</b> , 9, 322-330	0.6	3
20	Incretin Enhancers, Incretinomimetics [From Therapeutic Concept to Clinical Application. <i>Hungarian Medical Journal</i> , <b>2007</b> , 1, 133-146		
19	Neue Arzneimittel 2007. <b>2008</b> , 47-118		
18	Diagnosis, Evaluation, and Medical Management of Obesity and Diabetes. <b>2009</b> , 289-328		
17	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 23-30	3.4	1
16	Glucagon and the Glucagon-Like Peptides. <b>2010</b> , 660-672		
15	How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513		
14	Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents. <b>2011</b> , 275-310		
13	Sitagliptin monoterapisi ile kombinasyon tedavilerinin karlılığına ilişkin bir araştırma. <i>Uludağ Üniversitesi Tıp Fakültesi Dergisi</i> ,		
12	Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis.. <i>Journal of Cardiovascular Medicine</i> , <b>2022</b> , 23, 308-317	1.9	0
11	Weight Loss Medications and the Metabolic Syndrome. <b>2008</b> , 301-322		
10	Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. <i>Medscape Journal of Medicine</i> , <b>2008</b> , 10, 171		34
9	Incretin agents in type 2 diabetes. <i>Canadian Family Physician</i> , <b>2010</b> , 56, 639-48	0.9	30
8	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes. <i>P and T</i> , <b>2010</b> , 35, 509-13	1.4	32
7	Diabetes: glycaemic control in type 2 (drug treatments). <i>Clinical Evidence</i> , <b>2012</b> , 2012,		6
6	New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 864088	5.6	0
5	Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , <b>2022</b> , 77, 103633	2	0

4	Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , e068882	5.9	0
3	Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin. <i>Primary Care Diabetes</i> , <b>2022</b> ,	2.4	
2	Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes. <b>2022</b> , 22,		1
1	Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. <b>2023</b> , 13,		0